Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cobenfy in First Episode/Early Phase Schizophrenia
NCT06923891Phase 4Not yet recruiting
- Sponsor
- Vanguard Research Group
- Start
- Apr 2025
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of trospium in schizophrenia, sponsored by Vanguard Research Group. Primary endpoint: Medication Satisfaction Questionnaire at 12 weeks. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
trospium
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT06923891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06923891.